Although quite a number of studies have suggested that DCLK1 could be a risk factor and prognostic biomarker for malignant tumors, the relationships between expression level of DCLK1 and clinicopathological characteristics in tumors, especially for the clinical stage, lymph node metastasis and the degree of tumor differentiation, are still largely unknown and deserve further research. This evidence concerns the gene DCLK1 and neoplasm.